InflaRx N.V.

IFRX | NASDAQ

Price Alert Chart Builder DCF Calculator

$2.17

+$0.05 (+2.36%)

Sep 22, 2026, 2:00 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+2.36%

(1D)

Rating

Updated: Sep 10, 2026

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $318.89M

1D Range

2.04 2.18

52W Range

0.80 2.95

Valuation (TTM)

PE -3.71

PB 1.87

EV/EBITDA -2.98

Valuation (NTM)

Forward PE N/A

Forward PEG -0.14

Price Target $9

Cash Flow

FCF Yield -8.8%

SBC Adj. FCF Yield -7.5%

SBC Impact -15.0%

Margins

Gross Margin 48201.6%

Operating Margin 362271.5%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y -67.2% | 27.6%

Dil EPS 3Y | 5Y 22.4% | 9.7%

FCF 3Y | 5Y 26.2% | 8.9%

Returns

ROA -23.5%

ROE -58.0%

ROIC -24.9%

Financial Health

Net Cash

€158.18M ($180.67M)

Current Ratio 8.22

Interest Coverage -610.45

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

InflaRx N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and developing novel inhibitors leveraging C5a technology, primarily operating in Germany and the United States. The co...

Sector Healthcare

Industry Biotechnology

Employees 65

IPO Date Nov 6, 2017

Website www.inflarx.de

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 9, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

Upside

+314.75%

Buy (4)

Hold (1)

Sell (0)

Analyst Details ➞